Cargando…

Immune Cell and Biochemical Biomarkers in Advanced Laryngeal Cancer

OBJECTIVE: The aim of this study was to evaluate cell and biochemical biomarkers and establish their prognostic value in patients with advanced laryngeal cancer. MATERIAL AND METHODS: A prospective study included 52 patients with advanced laryngeal carcinoma surgically treated at the tertiary referr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jotic, Ana, Milovanovic, Jovica, Savic-Vujovic, Katarina, Radin, Zorana, Medic, Branislava, Folic, Miljan, Pavlovic, Bojan, Vujovic, Aleksandar, Dundjerovic, Dusko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309787/
https://www.ncbi.nlm.nih.gov/pubmed/35898723
http://dx.doi.org/10.1177/15593258221115537
Descripción
Sumario:OBJECTIVE: The aim of this study was to evaluate cell and biochemical biomarkers and establish their prognostic value in patients with advanced laryngeal cancer. MATERIAL AND METHODS: A prospective study included 52 patients with advanced laryngeal carcinoma surgically treated at the tertiary referral center. Tumor tissue was immunohistochemically stained for T-cell markers (CD4 and CD8), and levels of cytokines (IL-6 and IL-8) and C-reactive protein were analyzed from blood samples. RESULTS: Overall 3-year survival (OS) of patients included in the study was 69.2% and the disease specific survival (DSS) 72.5%. Higher expression of CD4(+) and CD8(+) were significant prognostic factors with positive impact on both OS and DSS in univariate analysis, but not in multivariate analysis. Levels of IL-8 were a significant predictor of 3-year OS and DSS survival in patients with advanced laryngeal cancer but not levels of IL-6 and CRP values. CONCLUSION: Though high expression of CD4 and CD8 were demonstrated in the tumor tissue, but their prognostic role was not established. Higher values of IL-8 proved to be significant negative predictor of DSS. This could further collaborate the inclusion of combination of biomarkers in assessment of favorable treatment choice in patients with advanced laryngeal carcinoma.